Dry Eye

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

Staying up-to-date on all things ocular is imperative in ocular surface disease.

Novel drops for a variety of indications are under investigation.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular surface.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

When combined, intense pulsed light and low-level light therapy—both of which have roots in dermatology—create a synergistic effect that treat dry eye more effectively than one therapy alone.

Modern technology enables early detection, individualized solutions.

Preservative-free eye drops offer benefits for ocular health.

Katherine M. Mastrota, OD, FAAO, advises on how to diagnosis this condition and not fall prey to a “knee-jerk” dry eye diagnosis.

When oral acne treatments lead to ocular surface disease, the solution lies in office-based therapies.

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

Bausch + Lomb and Novaliqu announced that the FDA has accepted its New Drug Application for NOV03, an investigational treatment for dry eye disease associated with meibomian gland dysfunction.

FDA-approved steroid offers short-term relief for ocular surface inflammation.

Ensure successful symptoms management with your patients.

Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

One OD shares his experience launching a successful social media campaign for Dry Eye Awareness month—and offers 3 tips for crafting a message to capture an audience's attention.

Contact lenses soaked in melatonin analogs may be able to address aqueous tear deficient dry eye disease, researchers say.

Lindsay A. Sicks, OD, FAAO, shares her number 1 tip for managing dry eye.

Case gives new perspective on subconjunctival hemorrhages

The first-of-its-kind alliance and latest phase of AOA's national public awareness campaign focuses on the effects of extended time on digital devices and its impact on eye health.

Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, shares his number 1 tip for managing dry eye.

Best practices to help patients enjoy their trip to the fullest.

Alissa M. Coyne, OD, FAAO, FASOS, gives her number 1 tip for managing dry eye.

Drug submission of the first water-free therapy took place at the end of June, according to the companies.

The company intends to develop the AcuStream technology for potential use with its current and future front-of-eye therapies, which may include lifitegrast ophthalmic solution for the treatment of dry eye disease.

Optometry Times'® Chief Optometric Editor Ben Casella, OD, FAAO, gives his number 1 tip for managing DED.